Nexus Drug Patent Portfolio
Nexus owns 1 orange book drug protected by 5 US patents Given below is the list of Nexus's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11090278 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same | 16 May, 2040 | Active |
| US11241400 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same | 16 May, 2040 | Active |
| US11464752 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same | 16 May, 2040 | Active |
| US11478436 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same | 16 May, 2040 | Active |
| US11571398 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same | 16 May, 2040 | Active |
Latest Legal Activities on Nexus's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Nexus.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Email Notification
Critical
| 14 Jun, 2023 | US11090278 (Litigated) |
|
Electronic Review
Critical
| 14 Jun, 2023 | US11241400 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 Jun, 2023 | US11090278 (Litigated) |
|
Email Notification
Critical
| 14 Jun, 2023 | US11464752 |
|
Electronic Review
Critical
| 14 Jun, 2023 | US11090278 (Litigated) |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 Jun, 2023 | US11464752 |
|
Email Notification
Critical
| 14 Jun, 2023 | US11478436 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 Jun, 2023 | US11241400 |
|
Electronic Review
Critical
| 14 Jun, 2023 | US11478436 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 Jun, 2023 | US11478436 |
|
Email Notification
Critical
| 14 Jun, 2023 | US11241400 |
|
Electronic Review
Critical
| 14 Jun, 2023 | US11464752 |
|
Email Notification
Critical
| 13 Jun, 2023 | US11571398 (Litigated) |
|
Electronic Review
Critical
| 13 Jun, 2023 | US11571398 (Litigated) |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 13 Jun, 2023 | US11571398 (Litigated) |
Nexus's Family Patents
Recent FDA approvals and tentative approvals for Nexus
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Minocycline Hydrochloride |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 12 Jun, 2025 |
Nexus Drug List
Given below is the complete list of Nexus's drugs and the patents protecting them.
1. Emerphed
Emerphed is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11090278 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
16 May, 2040
(14 years from now)
| Active |
| US11241400 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
16 May, 2040
(14 years from now)
| Active |
| US11464752 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
16 May, 2040
(14 years from now)
| Active |
| US11478436 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
16 May, 2040
(14 years from now)
| Active |
| US11571398 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
16 May, 2040
(14 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Emerphed's drug page